Sanofi has put off a biosimilar threat to Lantus till the end of 2016. In a patent settlement announced on Monday, the French drugmaker and U.S.-based Eli Lilly & Co. agreed to a royalty deal covering ...

After years of manufacturing woes torpedoed their chances to challenge Sanofi's blockbuster insulin injection Lantus, Mylan and Biocon recently received the FDA's go-ahead to launch their knockoff.

Levemir and Lantus are both long-acting injectable insulins that can be used for long-term management of diabetes. Insulin is a hormone that is naturally produced in the body by the pancreas. It helps ...

LAVAL, QC, Oct. 19 /CNW/ - Health Canada has approved the ClikSTAR reusable insulin pen for use with Lantus, giving patients with diabetes an additional option to safely and effectively achieve and ...

GoodRx, a resource for healthcare savings and information, is working with Sanofi, a company that specializes in diabetes care, to offer people living with diabetes access to Lantus (insulin glargine ...

Sanofi is facing further competition to its big-selling insulin drug Lantus in the UK, with Eli Lilly and Boehringer Ingelheim launching a biosimilar version this week. The biosimilar – called ...

Sanofi has inaugurated a new assembling and packaging line to produce its flagship pre-filled insulin injection pen Lantus SoloSTAR at its Beijing plant located at the Beijing Economic-Technological ...

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY. Similar to Lilly, Sanofi also said it is ...

(Reuters) - U.S. generics drugmaker Mylan said on Thursday that the United States Patent and Trademark Office had rejected Sanofi's infringement claims relating to insulin drug Lantus. Sanofi is ...